Aspen Pharmacare Holdings Limited (JSE:APN) is looking for acquisitions. Stephen Saad, Group Chief Executive said, "Both commercial pharma and manufacturing will show growth. The H2 revenue for commercial pharma, we expect to grow by ZAR 1 billion, underpinned, yes, by what we've -- more of what we've done in the first half, but together with the acquisitions, and will also represent the last half of any material impact of VBP.

And the Sandoz acquisition will restore the revenue from financial year '25. So when we say restore, it's not that it balances where it was, it will take us back to where we were before these VBP impacts. And that emerging market footprint is well positioned for future acquisitions and partnering opportunities".